| Vaccine efficacy trials for Crimean-Congo haemorrhagic fever: Insights from modelling different epidemiological settings.Vaccine | PMID 36058795无 PMCID | 2022-Sep-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.Vaccine | PMID 36064672无 PMCID | 2022-Sep-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.N Engl J Med | PMID 36129998无 PMCID | 2022-Sep-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.J Clin Oncol | PMID 35580297PMC9509093 | 2022-Sep-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.Antimicrob Agents Chemother | PMID 35943252PMC9487628 | 2022-Sep-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial.J Clin Oncol | PMID 35960897PMC9851703 | 2022-Sep-20 | 0.95 | The report is a randomized Phase III trial in human oncology with primary results including time-to-event efficacy endpoints (OS, DFS). However, it is excluded because the intervention is a non-drug radiation technique comparison, not a drug-containing intervention as required. | 待处理 |
| A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610.Jpn J Clin Oncol | PMID 35472141无 PMCID | 2022-Sep-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer - results of a randomized phase III trial (RAREST-02).BMC Cancer | PMID 36115962PMC9482290 | 2022-Sep-17 | 0.85 | The trial is a randomized Phase III study in human head-and-neck cancer, but the reported outcomes (acute toxicity rates) do not qualify as survival, progression, recurrence, death, hazard, or closely related efficacy outcomes for Kaplan-Meier digitization. | 待处理 |
| Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.Lancet | PMID 36116480无 PMCID | 2022-Sep-17 | 0.95 | The study is a randomized, Phase III trial of a drug intervention with primary efficacy results, but it is not an oncology study. The condition (uterine fibroids) is a non-cancerous neoplasm, and the primary endpoint (response rate at 24 weeks) is a binary outcome, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. | 待处理 |
| Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 36116481无 PMCID | 2022-Sep-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of hyperglycemia and computed tomographic perfusion deficits in patients who underwent endovascular treatment for acute ischemic stroke caused by a proximal intracranial occlusion: A subgroup analysis of a randomized phase 3 trial (MR CLEAN).J Neurol Sci | PMID 35834861无 PMCID | 2022-Sep-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Polypill Strategy in Secondary Cardiovascular Prevention.N Engl J Med | PMID 36018037无 PMCID | 2022-Sep-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial.Sci Bull (Beijing) | PMID 36546064无 PMCID | 2022-Sep-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.Blood Adv | PMID 35728048PMC9631625 | 2022-Sep-13 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.Clin Infect Dis | PMID 34864943PMC9464078 | 2022-Sep-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.Clin Infect Dis | PMID 34918028PMC9890454 | 2022-Sep-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.J Clin Oncol | PMID 35442766PMC9462531 | 2022-Sep-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.BMC Cancer | PMID 36088292PMC9464101 | 2022-Sep-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.BMC Cancer | PMID 36071409PMC9450379 | 2022-Sep-07 | 0.95 | While the record describes a Phase III randomized oncology trial with a drug intervention and reports original results, the primary efficacy endpoint is breast pathologic complete response (bpCR), which is a binary response endpoint, not a time-to-event outcome. No time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP, or mention of Kaplan-Meier or HR) is specified as primary or key secondary. | 待处理 |
| Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT).BMJ | PMID 36215226PMC9449358 | 2022-Sep-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials.BMC Gastroenterol | PMID 36064325PMC9446798 | 2022-Sep-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.BJS Open | PMID 36254732PMC9577542 | 2022-Sep-02 | 0.60 | Eligibility requires explicit drug intervention. This trial compares timing intervals after chemoradiotherapy (CRT), not a drug regimen. The abstract does not specify drug components of CRT (e.g., fluoropyrimidine), making drug intervention unconfirmed. Metadata cannot establish this criterion without inference. | 待处理 |
| First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.Haematologica | PMID 35021599PMC9425310 | 2022-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.J Clin Oncol | PMID 35442755无 PMCID | 2022-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation.Crit Care Med | PMID 35583232PMC9380150 | 2022-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Entire Versus Medial Supraclavicular Nodal Irradiation for Patients With High-Risk Node-Positive Breast Cancer.Int J Radiat Oncol Biol Phys | PMID 35654307无 PMCID | 2022-Sep-01 | 0.95 | The study is a retrospective analysis of two radiation techniques for breast cancer, not a randomized controlled trial. It reports survival outcomes but lacks randomization and a drug intervention. The publication_type tags are incorrect; the study itself is retrospective and non-randomized. | 待处理 |
| Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.J Clin Oncol | PMID 35666229PMC9426812 | 2022-Sep-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.Blood | PMID 35687757PMC9437710 | 2022-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.J Clin Oncol | PMID 35763704PMC9426828 | 2022-Sep-01 | 0.95 | The trial is a randomized Phase III oncology study with a drug intervention and reports original primary results. However, the primary efficacy endpoint is pathologic complete response (pCR), which is a binary outcome, not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The abstract does not mention Kaplan-Meier curves, hazard ratios, or any time-to-event analysis. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint. | 待处理 |
| Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.JAMA Dermatol | PMID 35857290PMC9301595 | 2022-Sep-01 | 0.95 | The trial is eligible on most criteria (oncology, human, randomized, Phase 3, drug intervention, original result), but it is excluded because the primary and reported efficacy endpoint is an index lesion response rate (ILRR), which is not a time-to-event endpoint. No time-to-event outcomes, survival analyses, Kaplan-Meier curves, or hazard ratios are reported in the abstract. | 待处理 |
| Clinical Evaluation of an HTK Solution for Liver Transplantation: A Phase 3 Randomized Pilot Clinical Trial Study.Arch Iran Med | PMID 37543887PMC10685771 | 2022-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.Diabetes Obes Metab | PMID 35589610PMC9540558 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Resistance training in advanced cancer: a phase II safety and feasibility trial-home versus hospital.BMJ Support Palliat Care | PMID 32792420无 PMCID | 2022-Sep | 0.85 | The record describes a Phase II randomized trial of resistance training in advanced cancer. It is not a Phase III/IIIb trial, does not involve a drug intervention, and reports no time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary outcomes are feasibility (adherence, acceptability) and safety, not efficacy survival analysis. Therefore, it is excluded based on multiple criteria. | 待处理 |
| Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.Clin Gastroenterol Hepatol | PMID 34274514无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia.J Geriatr Oncol | PMID 34521609无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.Eur Urol | PMID 34953603无 PMCID | 2022-Sep | 0.85 | The study is an eligible Phase III randomized oncology trial with time-to-event endpoints, but the intervention is a radiation technique (radiotherapy with focal boost), not a drug-containing therapy. It is therefore excluded from the drug-focused Kaplan-Meier digitization cohort. | 待处理 |
| Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).Br J Dermatol | PMID 34988975PMC9543168 | 2022-Sep | 0.85 | The study is a Phase II randomized trial in an oncology-related population with drug interventions, but it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) and does not report Kaplan-Meier or HR results for survival or progression. The primary endpoints are feasibility and actinic keratosis clearance, which are surrogate biomarkers, not formal time-to-event outcomes required for eligibility. | 待处理 |
| Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer.J Thorac Cardiovasc Surg | PMID 35012783无 PMCID | 2022-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial.Eur Urol Focus | PMID 35094962无 PMCID | 2022-Sep | 0.95 | The study is a substudy of a Phase III randomized trial but does not meet key eligibility criteria: it lacks a time-to-event efficacy endpoint and a drug-containing intervention. The focus is on patient awareness, not treatment efficacy. | 待处理 |
| Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.Mult Scler | PMID 35229668PMC9330270 | 2022-Sep | 0.95 | This is a safety/tolerability report from a long-term extension of Phase 3 and Phase 3b multiple sclerosis trials, not an oncology study. No efficacy outcomes related to survival, progression, or other oncology endpoints are reported. | 待处理 |
| Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.Mult Scler | PMID 35261318PMC9315182 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.Mult Scler | PMID 35266417PMC9315184 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.Pediatr Blood Cancer | PMID 35441463无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat.Clin Exp Nephrol | PMID 35462610PMC9385792 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).Br J Dermatol | PMID 35484697无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.Ophthalmology | PMID 35537533无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.Diabetes Obes Metab | PMID 35546450PMC9545869 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.Diabetes Obes Metab | PMID 35546790PMC9543252 | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.J Allergy Clin Immunol Pract | PMID 35568330无 PMCID | 2022-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.Eur Urol | PMID 35577644无 PMCID | 2022-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |